↓ Skip to main content

Dove Medical Press

Article Metrics

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Overview of attention for article published in Lung Cancer: Targets and Therapy, October 2011
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

patent
5 patents

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
26 Mendeley
Title
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
Published in
Lung Cancer: Targets and Therapy, October 2011
DOI 10.2147/lctt.s16440
Pubmed ID
Authors

Isamu Okamoto, Takeda, Nishimura, Nakagawa

Abstract

The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer.

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 23%
Professor > Associate Professor 5 19%
Researcher 5 19%
Other 4 15%
Student > Ph. D. Student 2 8%
Other 1 4%
Unknown 3 12%
Readers by discipline Count As %
Medicine and Dentistry 8 31%
Pharmacology, Toxicology and Pharmaceutical Science 4 15%
Agricultural and Biological Sciences 2 8%
Immunology and Microbiology 2 8%
Chemistry 2 8%
Other 4 15%
Unknown 4 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2016.
All research outputs
#5,607,547
of 17,359,532 outputs
Outputs from Lung Cancer: Targets and Therapy
#23
of 94 outputs
Outputs of similar age
#102,341
of 277,360 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#4
of 9 outputs
Altmetric has tracked 17,359,532 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 94 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.